Work Here?
Kenai Therapeutics
Work Here?
Allogeneic iPSC-derived dopamine neuron therapy
Kenai Therapeutics
Work Here?
Allogeneic iPSC-derived dopamine neuron therapy
Overview
Kenai Therapeutics develops allogeneic iPSC-based cell therapies for neurological disorders, with a focus on Parkinson’s disease. Its lead product, RNDP-001, uses donor-derived induced pluripotent stem cells to create dopamine progenitor cells that can be transplanted to replace lost dopamine neurons in the brain, providing an “off-the-shelf” treatment option rather than patient-specific cells. The company also builds a drug-discovery platform that uses its iPSC technology to create human models for identifying and testing new therapies. Unlike some rivals that rely on autologous cells, Kenai aims to offer scalable, broadly applicable therapies that can be produced in batches and used across many patients, complemented by validation in preclinical and clinical trials to obtain regulatory approval. Its goal is to bring safe, effective cell therapies and related drug candidates to market to improve outcomes for people with neurology disorders, starting with Parkinson’s disease.
About Kenai Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$97M
Headquarters
San Diego, California
Founded
2022
Get referred to Kenai Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Kenai won CIRM’s $8 million grant on January 5, 2026, extending runway.
- REPLACE completed enrollment on July 7, 2026, accelerating the first meaningful human dataset.
- Blake Arnold joined February 24, 2026, strengthening financing and partnership execution before expansion.
What critics are saying
- RNDP-001 remains unapproved; Kenai still needs 2026 safety, engraftment, and efficacy data.
- Aspen, UniXell, and XellSmart are advancing Parkinson’s iPSC competitors with stronger clinical readouts.
- One failed transplant or immune-safety event would crush investor confidence and end the platform.
What makes Kenai Therapeutics unique
- Kenai’s RNDP-001 uses off-the-shelf allogeneic iPSC dopamine progenitors, not patient-specific cells.
- FUJIFILM Cellular Dynamics gives Kenai scalable cryopreserved manufacturing for complex intracranial cell therapy.
- Fast Track plus a 2026 REPLACE enrollment completion show credible regulatory and execution momentum.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$97M
Above
Industry Average
Funded Over
4 Rounds
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 5%2 year growth
↑ 2%Kenai Therapeutics, a San Diego-based clinical-stage biotechnology company, has appointed Mark J. Gergen to its board of directors. Gergen brings over 30 years of experience in the life science industry, most recently serving in multiple executive roles at Poseida Therapeutics, including executive chairman and chief executive officer. The company is developing RNDP-001, an allogeneic cell therapy designed to replace dopamine-producing neurons lost to Parkinson's disease. The therapy is currently in Phase 1b/2a clinical trials and has received Fast Track designation from the US Food and Drug Administration. Kenai was founded in 2022 and uses an induced pluripotent stem cell platform to develop off-the-shelf neuron replacement therapies for neurological conditions.
Kenai Therapeutics, a San Diego-based biotechnology company, has secured an $8 million grant from the California Institute for Regenerative Medicine to advance clinical development of RNDP-001, a treatment for idiopathic Parkinson's disease. Founded in 2022, Kenai develops therapies for neurological disorders using induced pluripotent stem cells. RNDP-001 is an allogeneic neuron replacement therapy targeting the loss of dopamine-producing neurons, addressing the underlying cause rather than merely managing symptoms. The therapy is currently being evaluated in a Phase 1 open-label study called REPLACE, which assesses safety and efficacy in patients with moderate to severe Parkinson's disease. The US Food and Drug Administration has granted RNDP-001 Fast Track designation, expediting its development and review process for this condition affecting over 10 million people worldwide.
Ryne Biotechnology, a San Diego, CA-based therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to cure neurological disorders, received a $4M award from California Institute for Regenerative Medicine (CIRM).Led by Nick Manusos, Chief Executive Officer, and Howard Federoff, M.D., Ph.D., Chief Medical Officer, Ryne Bio is a biotechnology company pioneering next-generation approaches to cure neurological disorders. The company utilizes induced pluripotent stem cell (iPSC) technology, which enables scientists to manufacture any human cell, in order to advance its off-the-shelf neuron replacement therapeutics. The company intends to use the funds to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months. RNDP-001 has completed preclinical efficacy and safety studies. This CIRM award will allow Ryne Bio to finalize its IND-package including the production of GMP-grade materials to enable the evaluation of RNDP-001 in Phase 1 clinical trials for both inherited and idiopathic forms of Parkinson’s disease.Beyond RNDP-001, Ryne Bio is developing a platform of drug candidates, including next-generation, gene-modified programs that have the potential to modify and reverse disease progression in Parkinson’s disease and other moderate to severe central nervous system disorders.In addition to funding from CIRM, the company was launched and seeded in 2022 by Saisei Ventures, an emerging venture capital firm focused on building revolutionary advanced medicine companies.FinSMEs14/02/2023
Kenai Therapeutics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Kenai Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$97M
Headquarters
San Diego, California
Founded
2022
Kenai Therapeutics is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today